180 related articles for article (PubMed ID: 30390035)
1. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract][Full Text] [Related]
2. Follicular cells in pituitary neuroendocrine tumors.
Delfin L; Mete O; Asa SL
Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O; Cintosun A; Pressman I; Asa SL
Mod Pathol; 2018 Jun; 31(6):900-909. PubMed ID: 29434339
[TBL] [Abstract][Full Text] [Related]
4. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
5. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825
[TBL] [Abstract][Full Text] [Related]
6. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
7. Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas.
Asa SL; Puy LA; Lew AM; Sundmark VC; Elsholtz HP
J Clin Endocrinol Metab; 1993 Nov; 77(5):1275-80. PubMed ID: 8077321
[TBL] [Abstract][Full Text] [Related]
8. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
9. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
10. Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases.
Venable ER; Kerr SE; Lopes MBS; Jones KA; Bellizzi AM; Mounajjed T; Raghunathan A; Hamidi O; Halfdanarson TR; Ryder M; Graham RP
Diagn Pathol; 2020 Jul; 15(1):81. PubMed ID: 32622369
[TBL] [Abstract][Full Text] [Related]
11. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
Lidhar K; Korbonits M; Jordan S; Khalimova Z; Kaltsas G; Lu X; Clayton RN; Jenkins PJ; Monson JP; Besser GM; Lowe DG; Grossman AB
J Clin Endocrinol Metab; 1999 Oct; 84(10):3823-30. PubMed ID: 10523037
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.
Inoshita N; Yoshimoto T; Takazawa Y; Fukuhara N; Okada M; Nishioka H; Yamada S
Brain Tumor Pathol; 2023 Jul; 40(3):158-162. PubMed ID: 37072666
[TBL] [Abstract][Full Text] [Related]
13. Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype.
Taguchi A; Kinoshita Y; Amatya VJ; Onishi S; Go Y; Tominaga A; Takeshima Y; Yamasaki F; Horie N
Neurosurg Rev; 2023 Nov; 46(1):317. PubMed ID: 38030890
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
[TBL] [Abstract][Full Text] [Related]
15. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
16. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
17. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
[TBL] [Abstract][Full Text] [Related]
18. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.
Mete O; Gomez-Hernandez K; Kucharczyk W; Ridout R; Zadeh G; Gentili F; Ezzat S; Asa SL
Mod Pathol; 2016 Feb; 29(2):131-42. PubMed ID: 26743473
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
20. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
